vs
Riley Exploration Permian, Inc.（REPX）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Riley Exploration Permian, Inc.的1.2倍（$139.1M vs $113.9M），VERACYTE, INC.净利率更高（20.6% vs -61.8%，领先82.5%），VERACYTE, INC.同比增速更快（21.5% vs 11.2%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 3.9%）
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
REPX vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.2倍
$113.9M
营收增速更快
VCYT
高出10.3%
11.2%
净利率更高
VCYT
高出82.5%
-61.8%
两年增速更快
VCYT
近两年复合增速
3.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $113.9M | $139.1M |
| 净利润 | $-70.4M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | 38.3% | 16.3% |
| 净利率 | -61.8% | 20.6% |
| 营收同比 | 11.2% | 21.5% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-3.38 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REPXVCYT
| Q1 26 | $113.9M | $139.1M | ||
| Q4 25 | $97.3M | $140.6M | ||
| Q3 25 | $106.9M | $131.9M | ||
| Q2 25 | $85.4M | $130.2M | ||
| Q1 25 | $102.5M | $114.5M | ||
| Q4 24 | $102.7M | $118.6M | ||
| Q3 24 | $102.3M | $115.9M | ||
| Q2 24 | $105.4M | $114.4M |
净利润REPXVCYT
| Q1 26 | $-70.4M | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $16.3M | $19.1M | ||
| Q2 25 | $30.5M | $-980.0K | ||
| Q1 25 | $28.6M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $25.7M | $15.2M | ||
| Q2 24 | $33.5M | $5.7M |
毛利率REPXVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率REPXVCYT
| Q1 26 | 38.3% | 16.3% | ||
| Q4 25 | 26.9% | 26.4% | ||
| Q3 25 | 27.0% | 17.4% | ||
| Q2 25 | 33.7% | -4.0% | ||
| Q1 25 | 48.3% | 2.5% | ||
| Q4 24 | 31.2% | 3.5% | ||
| Q3 24 | 17.1% | 10.4% | ||
| Q2 24 | 50.9% | 4.0% |
净利率REPXVCYT
| Q1 26 | -61.8% | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | 15.3% | 14.5% | ||
| Q2 25 | 35.7% | -0.8% | ||
| Q1 25 | 27.9% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 25.1% | 13.1% | ||
| Q2 24 | 31.8% | 5.0% |
每股收益（稀释后）REPXVCYT
| Q1 26 | $-3.38 | $0.35 | ||
| Q4 25 | $4.02 | $0.50 | ||
| Q3 25 | $0.77 | $0.24 | ||
| Q2 25 | $1.44 | $-0.01 | ||
| Q1 25 | $1.36 | $0.09 | ||
| Q4 24 | $0.52 | $0.07 | ||
| Q3 24 | $1.21 | $0.19 | ||
| Q2 24 | $1.59 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $439.1M |
| 总债务越低越好 | $240.7M | — |
| 股东权益账面价值 | $553.4M | $1.3B |
| 总资产 | $1.2B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资REPXVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M |
总债务REPXVCYT
| Q1 26 | $240.7M | — | ||
| Q4 25 | $247.9M | — | ||
| Q3 25 | $367.0M | — | ||
| Q2 25 | $275.2M | — | ||
| Q1 25 | $249.3M | — | ||
| Q4 24 | $269.5M | — | ||
| Q3 24 | $288.6M | — | ||
| Q2 24 | $322.7M | — |
股东权益REPXVCYT
| Q1 26 | $553.4M | $1.3B | ||
| Q4 25 | $634.2M | $1.3B | ||
| Q3 25 | $566.5M | $1.3B | ||
| Q2 25 | $556.9M | $1.2B | ||
| Q1 25 | $532.4M | $1.2B | ||
| Q4 24 | $510.6M | $1.2B | ||
| Q3 24 | $507.4M | $1.2B | ||
| Q2 24 | $489.0M | $1.1B |
总资产REPXVCYT
| Q1 26 | $1.2B | $1.4B | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $994.9M | $1.3B | ||
| Q4 24 | $993.5M | $1.3B | ||
| Q3 24 | $997.9M | $1.3B | ||
| Q2 24 | $1.0B | $1.2B |
负债/权益比REPXVCYT
| Q1 26 | 0.43× | — | ||
| Q4 25 | 0.39× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $47.2M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 21.6% | — |
| 资本支出强度资本支出/营收 | 41.3% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流REPXVCYT
| Q1 26 | $47.2M | $35.2M | ||
| Q4 25 | $64.9M | $52.6M | ||
| Q3 25 | $63.6M | $44.8M | ||
| Q2 25 | $33.6M | $33.6M | ||
| Q1 25 | $50.4M | $5.4M | ||
| Q4 24 | $66.4M | $24.5M | ||
| Q3 24 | $72.1M | $30.0M | ||
| Q2 24 | $51.6M | $29.6M |
自由现金流REPXVCYT
| Q1 26 | $24.6M | — | ||
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | — | $27.7M | ||
| Q2 24 | — | $26.8M |
自由现金流率REPXVCYT
| Q1 26 | 21.6% | — | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | — | 24.8% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 23.4% |
资本支出强度REPXVCYT
| Q1 26 | 41.3% | — | ||
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 2.4% |
现金转化率REPXVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 3.90× | 2.34× | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.76× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 2.81× | 1.98× | ||
| Q2 24 | 1.54× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REPX
暂无分部数据
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
